Related Experiment Videos
Therapeutic potential of monovalent monoclonal antibodies
Abstract:
One therapeutic use for monoclonal antibody technology is the elimination of categories of unwanted cells by virtue of their distinct cell surface antigens. The efficiency of cell destruction by complement lysis or opsonization depends on a number of factors such as antibody specificity and isotype as well as certain properties of the target antigen. In some instances cells can escape destruction by redistributing and eventually losing the antigen-antibody complexes from their surface. This process, known as antigenic modulation, generally depends on bivalent antibody binding. Starting from the observation that rabbit antisera can be made more effective at killing tumour cells if they are first rendered univalent by limited proteolysis, we have now prepared a number of monovalent rat monoclonal antibodies to human cell-surface antigens. We find that these antibodies are no longer able to bring about modulation of their target antigens and have an enhanced facility for lysis with human complement. These special properties should greatly increase the therapeutic potential of monoclonal antibodies.
Insights
Monovalent monoclonal antibodies prevent tumor cell evasion of immune destruction. This enhancement in antibody function improves therapeutic potential for cancer treatment by increasing cell lysis.
Area of Science:
- Immunology
- Biotechnology
- Oncology
Background:
- Monoclonal antibody technology targets distinct cell surface antigens for eliminating unwanted cells.
- Therapeutic efficacy depends on antibody specificity, isotype, and target antigen properties.
- Antigenic modulation, where cells shed antigen-antibody complexes, can lead to treatment failure.
Purpose of the Study:
- To investigate the therapeutic potential of monovalent monoclonal antibodies.
- To determine if monovalent antibodies can overcome antigenic modulation.
- To assess the enhanced cell-killing capacity of monovalent antibodies.
Main Methods:
- Preparation of monovalent rat monoclonal antibodies against human cell-surface antigens.
- Assessment of antibody binding and subsequent cell surface antigen behavior.
- Evaluation of cell lysis efficiency using human complement.
Main Results:
- Monovalent antibodies prevented antigenic modulation of target antigens.
- Monovalent antibodies demonstrated enhanced cell lysis in the presence of human complement.
- These findings suggest a mechanism to improve antibody-mediated cell destruction.
Conclusions:
- Monovalent monoclonal antibodies are a promising therapeutic strategy.
- Overcoming antigenic modulation significantly enhances antibody-mediated cell killing.
- This approach holds potential for increasing the effectiveness of antibody-based therapies.